EMERGENCY contraceptives
containing levonorgestrel or
ulipristal acetate remain suitable
for women of all body weights in
preventing pregnancy, following
a review by the Committee for
Medicinal Products for Human
Use, which recommended that
these could be used, as the
benefits outweighed the risks
with effectiveness not significantly
impaired by excess body weight.
An EU-wide review was prompted
by changes to product information
for Norlevo in 2013 on the basis of
results from two clinical studies,
which stated it was less effective
in women weighing 75kg and not
effective in women weighing 80kg
or more (PD 03 Mar).
The Therapeutic Goods
Administration said it was aware
of the EMA’s recommendation
and that its review, which was
“almost complete”, would include
consideration of this finding.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 14
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.